Alterity Therapeutics Ltd
ATHE3.090USD
+0.060+1.98%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
47.01MMarket Cap
LossP/E TTM
More Details of Alterity Therapeutics Ltd Company
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Alterity Therapeutics Ltd Info
Ticker SymbolATHE
Company nameAlterity Therapeutics Ltd
IPO dateMar 28, 2000
CEOStamler (David A)
Number of employees9
Security typeDepository Receipt
Fiscal year-endMar 28
AddressLevel 14, 350 Collins Street
CityMELBOURNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code3000
Phone61393494906
Websitehttps://alteritytherapeutics.com/
Ticker SymbolATHE
IPO dateMar 28, 2000
CEOStamler (David A)
Company Executives of Alterity Therapeutics Ltd
Name
Name/Position
Position
Shareholding
Change
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Twin Lakes Capital
0.77%
Morgan Stanley & Co. LLC
0.38%
Homrich Berg
0.32%
Greenleaf Trust
0.18%
Citadel Advisors LLC
0.12%
Other
98.23%
Shareholders
Shareholders
Proportion
Twin Lakes Capital
0.77%
Morgan Stanley & Co. LLC
0.38%
Homrich Berg
0.32%
Greenleaf Trust
0.18%
Citadel Advisors LLC
0.12%
Other
98.23%
Shareholder Types
Shareholders
Proportion
Private Equity
0.77%
Research Firm
0.42%
Investment Advisor/Hedge Fund
0.36%
Bank and Trust
0.18%
Hedge Fund
0.12%
Other
98.16%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
31
335.79K
1.62%
--
2025Q3
31
335.79K
1.62%
+112.77K
2025Q2
26
223.02K
2.05%
-19.87K
2025Q1
25
242.89K
2.06%
+14.64K
2024Q4
25
125.45K
2.26%
+11.61K
2024Q3
25
113.89K
1.99%
+34.70K
2024Q2
24
79.19K
2.01%
-15.98K
2024Q1
24
95.17K
1.68%
-51.08K
2023Q4
23
88.25K
2.56%
+29.17K
2023Q3
26
59.08K
3.01%
-573.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Twin Lakes Capital
5.92K
0.03%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
58.23K
0.32%
+14.60K
+33.46%
Jun 30, 2025
Homrich Berg
--
0%
-37.48K
-100.00%
Jun 30, 2025
Greenleaf Trust
17.00K
0.09%
+17.00K
--
Jun 30, 2025
BNP Paribas Securities Corp. North America
8.19K
0.05%
-1.56K
-16.02%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.16K
0.01%
--
--
Aug 31, 2025
Rhumbline Advisers Ltd. Partnership
130.00
0%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Date
Type
Ratio
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
FAQs
Who are the top five shareholders of Alterity Therapeutics Ltd?
The top five shareholders of Alterity Therapeutics Ltd are:
Twin Lakes Capital holds 5.92K shares, accounting for 0.03% of the total shares.
Morgan Stanley & Co. LLC holds 58.23K shares, accounting for 0.32% of the total shares.
Homrich Berg holds 0.00 shares, accounting for 0.00% of the total shares.
Greenleaf Trust holds 17.00K shares, accounting for 0.09% of the total shares.
BNP Paribas Securities Corp. North America holds 8.19K shares, accounting for 0.05% of the total shares.
Twin Lakes Capital holds 5.92K shares, accounting for 0.03% of the total shares.
Morgan Stanley & Co. LLC holds 58.23K shares, accounting for 0.32% of the total shares.
Homrich Berg holds 0.00 shares, accounting for 0.00% of the total shares.
Greenleaf Trust holds 17.00K shares, accounting for 0.09% of the total shares.
BNP Paribas Securities Corp. North America holds 8.19K shares, accounting for 0.05% of the total shares.
What are the top three shareholder types of Alterity Therapeutics Ltd?
The top three shareholder types of Alterity Therapeutics Ltd are:
Twin Lakes Capital
Morgan Stanley & Co. LLC
Homrich Berg
Twin Lakes Capital
Morgan Stanley & Co. LLC
Homrich Berg
How many institutions hold shares of Alterity Therapeutics Ltd (ATHE)?
As of 2025Q4, 31 institutions hold shares of Alterity Therapeutics Ltd, with a combined market value of approximately 335.79K, accounting for 1.62% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Alterity Therapeutics Ltd?
In --, the -- business generated the highest revenue for Alterity Therapeutics Ltd, amounting to -- and accounting for --% of total revenue.
